Thera-SAbDab

PLOZALIZUMAB

>   Structural Summary
TherapeuticPlozalizumab
TargetCCR2
Heavy ChainEVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS
Light ChainDVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyHumanization by CDR Grafting
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedMillennium, Millennium Pharmaceuticals, Takeda, Takeda Oncology
Conditions Approvedna
Conditions ActiveAtherosclerosis, Diabetic nephropathies, Malignant melanoma
Conditions DiscontinuedMultiple sclerosis, Rheumatoid arthritis, Scleroderma, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]